Founded in 2016, today A-Mansia Biotech is a SME driven by 14 microbiome passionate people.
Akkermansia muciniphila isolation, identification and characterization by Prof. Willem M. de Vos (Wageningen University – The Netherlands) and his team
Collaboration between the teams of Prof. Willem M. de Vos (Wageningen University – The Netherlands) and Prof. Patrice D. Cani (UCLouvain – Belgium).
They demonstrate the efficacy of Akkermansia muciniphila supplementation in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity
Demonstration of higher efficiency of the pasteurized Akkermansia muciniphila compared to the live bacterium in the prevention of gut barrier dysfunction, obesity, diabetes and related metabolic disorders in preclinical models of obesity
Foundation of A-Mansia Biotech S.A. by Professors Patrice D. Cani and Willem M. de Vos.
First high-scale production of Akkermansia muciniphila at a quality level suitable to begin clinical studies. The ethical committee gives its approval for the Microbes4U study
Series A fundraising with Seventure and IFF as lead investors and SOPARTEC/Vives, SRIW and non-dilutive support from the Walloon Region.
Jean-Christophe Malrieu was appointed as the first CEO. He managed the series A financing, the building of the company and its product strategy.
Publication of the Microbes4U© study results in Nature Medicine : the first randomized double-blind placebo-controlled pilot study in human volunteers demonstrates that daily administration of pasteurized Akkermansia muciniphila for 3 months is safe, well tolerated and reduces cardiometabolic risk factors (pre-diabetes, hypercholesterolemia, low-grade inflammation)
Application for the approval of pasteurised Akkermansia muciniphila as a novel food ingredient in the European Union
Publication of the toxicological safety evaluation of pasteurized Akkermansia muciniphila.
Michael Oredsson is appointed as CEO.